天津医药

• 药物临床观察 • 上一篇    下一篇

羟乙基淀粉联合依达拉奉治疗进展性卒中的疗效研究

陈丽   

  1. 天津市天和医院
  • 收稿日期:2012-02-29 修回日期:2012-04-17 出版日期:2012-08-15 发布日期:2012-08-15
  • 通讯作者: 陈丽

Analysis of hydroxyethyl starch combined with Edaravone to treat progressive stroke

li chen   

  • Received:2012-02-29 Revised:2012-04-17 Published:2012-08-15 Online:2012-08-15
  • Contact: li chen

PDF (PC)

2341

摘要： 【摘要】目的：探讨羟乙基淀粉联合依达拉奉治疗进展性卒中的疗效。方法：将我院2010年1月到2011年11月收治的进展性脑卒中患者10O例随机分为对照组与治疗组，每组50例。对照组给予常规治疗，治疗组在常规治疗基础上增加羟乙基淀粉和依达拉奉治疗。两组均连续治疗14天。在治疗前后对两组患者治疗进行卒中量表(NIHSS)评分及日常生活能力(BI)评分，并观察不良反应的发生情况。结果：治疗组的N1HSS评分及BI评分明显优于对照组(P<0．05)；两组不良反应发生率比较无统计学意义(P>0．05)。结论：羟乙基淀粉联合依达拉奉治疗进展性脑卒中的疗效确切，没有明显不良反应，值得临床推广。

关键词: 羟乙基淀粉, 依达拉奉, 进展性脑卒中

Abstract: Object To discuss the treatment of progressive stroke with hydroxyethyl starch combined Edaravone. Method A retrospective analysis of 100 patients with progressive stroke from Jan 2010 to Nov 2011. All of these paitents were randomly divided into two groups, 50 patients in each group. The treatment group was treated with hydroxyethyl starch and Edaravone on the base of routine treatment. The control group was just given the routine treatment. Both groups were treated for two weeks continuously. The National institute of Health Stroke Scale (NIHSS ) and Barthel index (BI) were measured before and after the treatment，the adverse reactions were evaluated. Results The scoreing of NIHSS and BI in treatment group were much higher than control group(P<0.05).The different of adverse reactions in both groups were not significant (P > 0.05 ). Conclusions The treatment of progressive stroke with hydroxyethyl starch combined Edaravone has sure curative effect, and no significant adverse reactions.

Key words: hydroxyethyl starch, Edaravone, progressive stroke